Rafoxanide and Closantel Inhibit SPAK and OSR1 Kinases by Binding to a Highly Conserved Allosteric Site on Their C-terminal Domains

  • Mubarak A. AlAmri
  • , Hachemi Kadri
  • , Luke J. Alderwick
  • , Nigel S. Simpkins
  • , Youcef Mehellou

Research output: Contribution to journalArticlepeer-review

41 Scopus citations

Abstract

SPAK and OSR1 are two protein kinases that have emerged as attractive targets in the discovery of novel antihypertensive agents due to their role in regulating electrolyte balance in vivo. Herein we report the identification of an allosteric pocket on the highly conserved C-terminal domains of these two kinases, which influences their activity. We also show that some known WNK signaling inhibitors bind to this allosteric site. Using in silico screening, we identified the antiparasitic agent rafoxanide as a novel allosteric inhibitor of SPAK and OSR1. Collectively, this work will facilitate the rational design of novel SPAK and OSR1 kinase inhibitors that could be useful antihypertensive agents.

Original languageEnglish
Pages (from-to)639-645
Number of pages7
JournalChemMedChem
Volume12
Issue number9
DOIs
StatePublished - 9 May 2017
Externally publishedYes

Keywords

  • allosteric inhibitors
  • hypertension
  • kinases
  • OSR1
  • SPAK

Fingerprint

Dive into the research topics of 'Rafoxanide and Closantel Inhibit SPAK and OSR1 Kinases by Binding to a Highly Conserved Allosteric Site on Their C-terminal Domains'. Together they form a unique fingerprint.

Cite this